Quarterly report pursuant to Section 13 or 15(d)

Segment Disclosures

v3.22.1
Segment Disclosures
 3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Disclosures Segment Disclosures
 
The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.

The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.
 
Segment reporting information is as follows:
  EksoHealth EksoWorks Total
Three months ended March 31, 2022      
Revenue $ 1,881  $ 686  $ 2,567 
Cost of revenue 1,015  343  1,358 
Gross profit $ 866  $ 343  $ 1,209 
Three months ended March 31, 2021      
Revenue $ 1,727  $ 183  $ 1,910 
Cost of revenue 542  133  675 
Gross profit $ 1,185  $ 50  $ 1,235 

Geographically, the regions the Company operates in are the Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC). Individual countries with revenue greater than 10% of total revenue are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:
  Three Months Ended March 31,
  2022 2021
United States $ 1,343  $ 982 
Other 55  36 
Americas 1,398  1,018 
Germany 124  437 
Other 440  186 
EMEA 564  623 
Japan 280  19 
Singapore 48  241 
Other 277  9 
APAC 605  269 
  $ 2,567  $ 1,910